Tag:
Ben Venue Labs
Latest Headlines
Latest Headlines
Ben Venue lengthens remediation timeline
Ben Venue Labs is extending the timeline for remediation at an Ohio plant—and along with it the expected availability of some critical drugs currently in short supply. The company made the
J&J releases Doxil batch; Ben Venue troubles detailed in FDA report
An in-process batch of cancer drug Doxil, halted at Ben Venue Labs when the contract manufacturer suspended operations due to QA concerns, has cleared the scrutiny of Johnson & Johnson ( $JNJ ) and
Europe issues 2nd recall of drugs made by Ben Venue
Ben Venue is back in the news for product quality shortcomings with Europe's recommendation Friday of additional precautionary drug recalls. The European Medicines Agency issued a similar recall for
Theravance MRSA drug a victim of Ben Venue shutdown
Vibativ, an injectable skin-infection treatment from Theravance ($THRX) that's marketed by Astellas, has fallen victim to the QA-related production shutdown at contractor Ben Venue's plant in
Europe takes precautions with Ben Venue drugs
Ben Venue 's manufacturing QA troubles, which prompted the voluntary closing of its Bedford, OH plant, have rippled across the Atlantic. The European Medicines Agency issued a precautionary recall of
Ben Venue shutdown strains J&J drug supply
The Ben Venue unit of Boehringer Ingelheim has temporarily suspended drug manufacture and distribution at its Bedford, OH, facility. The voluntary action is expected to further strain supplies of
Turbulence ahead for cancer drugs with Ben Venue exit
In contrast to Sagent Pharmaceutical's ( $SGNT ) half-full view of the drug-shortage glass, Boehringer Ingelheim apparently sees it as half empty. And leaking. Boehringer has decided it's time for its
Ben Venue having trouble filling jobs at Ohio plant
Although the pharma industry has eliminated 35,000 jobs so far this year , drugmakers are having a tough time finding the manufacturing help they need. Many of the layoffs have been in sales and even
